Cubist Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Trius Therapeutics

  Cubist Pharmaceuticals Commences Tender Offer for All Outstanding Shares of
  Trius Therapeutics

        Tender Offer Consistent with Terms Announced on July 30, 2013

Business Wire

LEXINGTON, Mass. -- August 13, 2013

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the commencement
of its tender offer for all outstanding shares of the common stock of Trius
Therapeutics (NASDAQ: TSRX) for $13.50 per share in cash, plus one Contingent
Value Right, entitling the holder to receive an additional cash payment of up
to $2.00 for each share they tender if certain sales milestones are achieved.
The tender offer is being made by BRGO Corporation, a wholly-owned subsidiary
of Cubist, pursuant to the previously announced Agreement and Plan of Merger,
dated July 30, 2013, for Cubist to acquire Trius.

The tender offer and merger are subject to the satisfaction or waiver of
customary conditions, including, among others, that the number of shares
validly tendered and not validly withdrawn equals at least a majority of the
outstanding shares on a fully-diluted basis and that any applicable waiting
periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended, have expired or otherwise been terminated.

Cubist filed today with the U.S. Securities and Exchange Commission (SEC) a
Tender Offer Statement on Schedule TO, setting forth in detail the terms of
the tender offer. Trius also filed today with the SEC a
Solicitation/Recommendation Statement on Schedule 14D-9, setting forth in
detail, among other things, the unanimous recommendation of Trius’ Board of
Directors that Trius’ stockholders accept the tender offer and tender their
shares in the offer. Copies of the Offer to Purchase, Letter of Transmittal
and other materials related to the tender offer are available free of charge
from MacKenzie Partners, Inc., the information agent for the tender offer, at
(212) 929-5500 for banks and brokers or toll-free at (800) 322-2885 for
stockholders and all others. Computershare Trust Company, N.A., is acting as
depositary for the tender offer.

The tender offer and any withdrawal rights to which Trius’ stockholders may be
entitled expire at 9:00 a.m., Eastern Time, on September 11, 2013, unless
extended or earlier terminated.

About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
research, development, and commercialization of pharmaceutical products that
address significant unmet medical needs in the acute care environment. Cubist
is headquartered in Lexington, Mass. Additional information can be found at
Cubist’s web site at www.cubist.com.

Notice to Investors
This press release is for informational purposes only and is not an offer to
purchase nor a solicitation of an offer to sell securities. The solicitation
and the offer to purchase shares of Trius common stock are being made only
pursuant to the Offer to Purchase, Letter of Transmittal and related materials
that Cubist and BRGO Corporation have filed with the SEC on a Tender Offer
Statement on Schedule TO on August 13, 2013. Trius also has filed a
Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the
offer on August 13, 2013. Trius stockholders and other investors should read
these materials carefully because they contain important information,
including the terms and conditions of the offer. Trius stockholders and other
investors may obtain free copies of the Tender Offer Statement,
Solicitation/Recommendation Statement and other documents filed with the SEC
through the web site maintained by the SEC at www.sec.gov. In addition,
investors and security holders will be able to obtain free copies of these
documents from Cubist or Trius by contacting: MacKenzie Partners, Inc. on
behalf of Cubist toll free at (800) 322-2885 or collect at (212) 929-5500 or
tenderoffer@mackenziepartners.com; or Stefan Loren at Westwicke Partners, LLC
on behalf of Trius at (443) 213-0507 or sloren@westwicke.com. Questions and
requests for assistance or for additional copies of these documents may be
directed to MacKenzie Partners, Inc., the information agent for the offer, at
(212) 929-5500 for banks and brokers or toll-free at (800) 322-2885 for
stockholders and all others.

Contact:

INVESTORS:
Cubist
Eileen C. McIntyre, 781-860-8533
Vice President, Investor Relations
eileen.mcintyre@cubist.com
or
MacKenzie Partners, Inc.
Mark Harnett, 212-929-5500
tenderoffer@mackenziepartners.com
or
MEDIA:
Julie DiCarlo, 781-860-8063
Senior Director, Corporate Communications
julie.dicarlo@cubist.com
 
Press spacebar to pause and continue. Press esc to stop.